Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers

Next Previous
X
Search
Trial Profile

A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUP 16 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms AP-W-CLI-2018-8
  • Sponsors Aurealis Pharma

    • Most Recent Events

    • 13 Nov 2024 According to an Aurealis Therapeutics media release, company raises CHF 8 Million and the funds will be primarily used to complete Phase 2 clinical studies
    • 04 Nov 2024 Results presented in an Aurealis Therapeutics Media Release
    • 04 Nov 2024 According to an Aurealis Therapeutics media release, company announced publication in the peer-reviewed journal Therapeutic Advances in Endocrinology and Metabolism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top